Department of Obstetrics, Gynecology, and Reproductive Sciences, McGovern Medical School, and the Center for Clinical Research and Evidence-Based Medicine, Department of Pediatrics, University of Texas Health Science Center at Houston, Houston, Texas.
Obstet Gynecol. 2018 Dec;132(6):1358-1367. doi: 10.1097/AOG.0000000000002970.
Among uncomplicated pregnancies, serial third-trimester ultrasound examinations identified significantly more cases with a composite of fetal growth or amniotic fluid abnormalities (27%) than did routine fundal height measurements (8%).
Women without complications between 24 0/7 and 30 6/7 weeks of gestation were randomized (NCT0270299) to either routine care (control arm) or ultrasound examination every 4 weeks (intervention arm). The primary outcome was a composite of abnormalities of fluid volume and growth: oligohydramnios or polyhydramnios; fetal growth restriction; or large for gestational age. The secondary outcome was the presence of composite maternal or neonatal morbidity among the two groups. A total of 206 participants was needed to have 80% power to detect an increase in the primary composite outcome from 10% in control to 25% in the intervention group (baseline rate 10%; two-tailed; α=0.05; loss to follow-up 5%). All women were included in the intent-to-treat analysis. Fisher exact, χ tests, or two-sample t tests were used to assess group differences.
From July 11, 2016, to May 24, 2017, 852 women were screened for eligibility and 206 were randomized as follows: 102 in routine care and 104 in serial ultrasound examinations. The two groups were comparable in baseline characteristics. The primary composite outcome was significantly higher among women who were in the ultrasound examination group than the routine care group (27% vs 8%; relative risk 3.43, 95% CI 1.64-7.17); five women (95% CI 3-11) were needed to identify at least one of the composite ultrasound abnormalities. Although we were underpowered to detect a significant difference, the following secondary endpoints occurred with similar frequency in the ultrasound examination group than the routine care group: induction resulting from abnormal ultrasound examination findings (14% vs 6%), cesarean delivery in labor (5% vs 6%), and prespecified composite maternal morbidity (9% in both groups) and composite neonatal morbidity (1% vs 4%).
Among uncomplicated pregnancies between 24 0/7 and 30 6/7 weeks of gestation, serial third-trimester ultrasound examinations were significantly more likely to identify abnormalities of fetal growth or amniotic fluid than measurements of fundal height and indicated ultrasound examination. No differences in maternal and neonatal outcomes were noted, although we were underpowered for these endpoints.
ClinicalTrials.gov, NCT02702999.
在无并发症的妊娠中,连续的孕晚期超声检查发现胎儿生长或羊水异常的复合病例(27%)明显多于常规宫底高度测量(8%)。
在 24 0/7 至 30 6/7 周之间无并发症的孕妇被随机分配(NCT0270299)至常规护理(对照组)或每 4 周进行一次超声检查(干预组)。主要结局是羊水体积和生长异常的复合:羊水过少或羊水过多;胎儿生长受限;或大于胎龄儿。次要结局是两组中复合产妇或新生儿发病率的存在。需要 206 名参与者才能有 80%的效力来检测对照组中主要复合结局(从 10%增加到干预组的 25%)(基线率 10%;双侧;α=0.05;随访丢失 5%)。所有妇女均纳入意向治疗分析。Fisher 确切检验、χ检验或两样本 t 检验用于评估组间差异。
从 2016 年 7 月 11 日至 2017 年 5 月 24 日,共有 852 名妇女接受了资格筛选,206 名妇女被随机分配如下:常规护理组 102 名,连续超声检查组 104 名。两组在基线特征方面具有可比性。在超声检查组中,主要复合结局明显高于常规护理组(27% vs 8%;相对风险 3.43,95%CI 1.64-7.17);需要 5 名妇女(95%CI 3-11)才能确定至少一种超声异常。尽管我们没有足够的效力来检测到显著差异,但超声检查组和常规护理组的以下次要终点发生频率相似:因超声检查结果异常而进行的引产(14% vs 6%)、产时剖宫产(5% vs 6%)以及预定的复合产妇发病率(两组均为 9%)和复合新生儿发病率(1% vs 4%)。
在 24 0/7 至 30 6/7 孕周之间的无并发症妊娠中,连续的孕晚期超声检查比宫底高度测量更有可能识别胎儿生长或羊水异常,并提示进行超声检查。虽然我们对这些终点的效力不足,但没有发现母婴结局的差异。
ClinicalTrials.gov,NCT02702999。